[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,591,419
  • Shares Outstanding, K 71,075
  • Annual Sales, $ 0 K
  • Annual Income, $ -141,200 K
  • EBIT $ -320 M
  • EBITDA $ -318 M
  • 60-Month Beta -1.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.43

Options Overview Details

View History
  • Implied Volatility 101.07% (+2.26%)
  • Historical Volatility 50.22%
  • IV Percentile 85%
  • IV Rank 17.93%
  • IV High 297.52% on 12/05/25
  • IV Low 58.16% on 03/17/26
  • Expected Move (DTE 15) 6.97 (13.25%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 215
  • Volume Avg (30-Day) 244
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 12,756
  • Open Int (30-Day) 13,200
  • Expected Range 45.65 to 59.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 6
  • High Estimate $-0.35
  • Low Estimate $-0.43
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.80 +17.46%
on 07/17/26
57.07 -7.80%
on 07/07/26
-2.13 (-3.89%)
since 07/06/26
3-Month
35.78 +47.07%
on 05/18/26
57.07 -7.80%
on 07/07/26
+11.78 (+28.84%)
since 05/06/26
52-Week
15.85 +231.99%
on 08/07/25
94.90 -44.55%
on 12/08/25
+36.31 (+222.62%)
since 08/06/25

Most Recent Stories

More News
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist)  Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral...

GPCR : 52.62 (+4.14%)
Structure Therapeutics' Clinical Pipeline Timeline Is About to Define Its Valuation Multiple

Barchart Research What to Expect from GPCR Earnings GPCR Generated August 4, 2026 Current Price $49.64 EPS Estimate $$-0.39 Consensus Rating Strong Buy Average Move 3.94% Structure Therapeutics' Clinical...

GPCR : 52.62 (+4.14%)
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule...

GPCR : 52.62 (+4.14%)
Structure Therapeutics Announces Participation in Upcoming Investor Conferences

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 52.62 (+4.14%)
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Reported positive results from aleniglipron Phase 2 ACCESS II study  with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially...

GPCR : 52.62 (+4.14%)
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 52.62 (+4.14%)
3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

NVO : 45.97 (+3.23%)
OZEM : 32.86 (+1.24%)
LLY : 1,191.94 (+1.89%)
GPCR : 52.62 (+4.14%)
THNR : 26.00 (+0.85%)
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 52.62 (+4.14%)
3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

VKTX : 33.30 (-0.63%)
LLY : 1,191.94 (+1.89%)
GPCR : 52.62 (+4.14%)
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral...

GPCR : 52.62 (+4.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 56.35
2nd Resistance Point 54.57
1st Resistance Point 53.59
Last Price 52.62
1st Support Level 50.83
2nd Support Level 49.05
3rd Support Level 48.07

See More

52-Week High 94.90
Fibonacci 61.8% 64.70
Fibonacci 50% 55.38
Last Price 52.62
Fibonacci 38.2% 46.05
52-Week Low 15.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.